Specialty cancer diagnostics company Precipio Inc. (NASDAQ: PRPO) will host its Q2-2026 shareholder update call on August 17, 2026, at 5:00 PM ET. The conference call aims to provide investors with insights into the company’s operational progress and strategic direction. CEO Ilan Danieli stated that the team continues to make solid progress in adding customers and expanding its pipeline, which will be reflected in the upcoming numbers. This update serves as a key communication channel for stakeholders seeking clarity on the company’s performance trajectory.

Call Agenda and Participation

The agenda for the August 17 call includes remarks on Precipio’s current core businesses followed by a moderated live Q&A session. Management intends to address investor questions regarding performance, strategy, and growth initiatives. Participants wishing to ask questions during the live call must log into the Q&A system and identify themselves along with their organization or status as individual investors.

Investors may also submit questions in advance by emailing investors@precipiodx.com . Management indicated it would do its best to address these pre-submitted queries during the broadcast. The conference call can be accessed by dialing 646.307.1865 and requesting the Precipio Inc. conference call.

Access and Replay Details

A replay of the call will be available approximately 24 hours after the live event. Listeners can access the replay via the Investors page on Precipio’s website at https://www.precipiodx.com/investors/ . The company encourages regular review of its website and social media channels, including X (@PrecipioDx) and LinkedIn, as material information may be posted there.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address cancer misdiagnoses by developing diagnostic products and services that deliver higher accuracy and improved laboratory workflow. These solutions aim to improve patient outcomes and reduce healthcare expenses. Precipio develops innovative technologies in its laboratory, where it designs, tests, validates, and uses products clinically before commercializing them for the global laboratory community.

Precipio is requesting shareholders to instruct their brokers to vote their shares immediately to avoid the high additional costs associated with adjourning its Annual Shareholders Meeting. The company needs a minimum of 50% of shares to be voted to establish a quorum, but only approximately 42% of shares have been voted at the time of this press release. The Annual Meeting is scheduled for June 15, 2026, at 10 a.m. Eastern Time.

Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be counted at the meeting. Management emphasized that whether shareholders intend to vote for or against the proposals, submitting voting instructions is critical to ensuring the shares count toward the quorum. If the company does not receive sufficient votes, it may need to adjourn and reconvene the meeting, resulting in avoidable expenses.

Meeting Details and Requirements

The following table outlines the key dates and voting thresholds for the upcoming meeting:

Precipio operates as a healthcare biotechnology company focused on cancer diagnostics. The company develops diagnostic products and services to address cancer misdiagnoses, aiming to improve accuracy and patient outcomes while reducing healthcare expenses.